AAAAAA
Results: 1-25/34
Authors:
Gitlitz, BJ
Hoffman, DMJ
Moldawer, N
Belldegrun, A
Figlin, RA
Citation: Bj. Gitlitz et al., Treatment of metastatic renal cell carcinoma with high-dose bolus interleukin-2 in a non-intensive care unit: An analysis of 124 consecutively treated patients, CANCER J, 7(2), 2001, pp. 112-120
Authors:
Belldegrun, A
Citation: A. Belldegrun, What's hot in the prostate?, PROSTATE C, 4(1), 2001, pp. 1-2
Authors:
Belldegrun, A
Tso, CL
Zisman, A
Naitoh, J
Said, J
Pantuck, AJ
Hinkel, A
de Kernion, J
Figlin, R
Citation: A. Belldegrun et al., Interleukin 2 gene therapy for prostate cancer: Phase I clinical trial andbasic biology, HUM GENE TH, 12(8), 2001, pp. 883-892
Authors:
Wu, L
Matherly, J
Smallwood, A
Adams, JY
Billick, E
Belldegrun, A
Carey, M
Citation: L. Wu et al., Chimeric PSA enhancers exhibit augmented activity in prostate cancer gene therapy vectors, GENE THER, 8(18), 2001, pp. 1416-1426
Authors:
Pantuck, AJ
Zisman, A
Belldegrun, A
Citation: Aj. Pantuck et al., Gene and immune therapy for renal cell carcinoma, INT J UROL, 8(7), 2001, pp. S1-S4
Authors:
Pantuck, AJ
Zisman, A
Henderson, D
Wilson, D
Schreiber, A
Belldegrun, A
Citation: Aj. Pantuck et al., New biologicals for prostate cancer prevention: Genes, vaccines, and immune-based interventions, UROLOGY, 57(4A), 2001, pp. 95-99
Authors:
Belldegrun, A
Bander, NH
Lerner, SP
Wood, DP
Pantuck, AJ
Citation: A. Belldegrun et al., Society of urologic oncology biotechnology forum: New approaches and targets for advanced prostate cancer, J UROL, 166(4), 2001, pp. 1316-1321
Authors:
Tso, CL
Zisman, A
Pantuck, A
Calilliw, R
Hernandez, JM
Paik, S
Nguyen, D
Gitlitz, B
Shintaku, PI
de Kernion, S
Figlin, R
Belldegrun, A
Citation: Cl. Tso et al., Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 andGranulocyte/Monocyte-Colony stimulating factor, CANCER RES, 61(21), 2001, pp. 7925-7933
Authors:
Patel, B
Belldegrun, A
Citation: B. Patel et A. Belldegrun, Interferon alpha, GM-CSF-Activated T cells, and IL-6 in renal cell carcinoma, METH MOL M, 53, 2001, pp. 301-312
Authors:
Zisman, A
Pantuck, AJ
Belldegrun, A
Citation: A. Zisman et al., Gene and immune-based therapies for genitourinary malignancies: Current status and future prospects, ISR MED ASS, 2(1), 2000, pp. 33-42
Authors:
Tso, CL
McBride, WH
Sun, JR
Patel, B
Tsui, KH
Paik, SH
Gitlitz, B
Caliliw, R
van Ophoven, A
Wu, L
deKernion, J
Belldegrun, A
Citation: Cl. Tso et al., Androgen deprivation induces selective outgrowth of aggressive hormone-refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells, CANCER J, 6(4), 2000, pp. 220-233
Authors:
Hinkel, A
Tso, CL
Gitlitz, BJ
Neagos, N
Schmid, I
Paik, SH
deKernion, J
Figlin, R
Belldegrun, A
Citation: A. Hinkel et al., Immunomodulatory dendritic cells generated from nonfractionated bulk peripheral blood mononuclear cell cultures induce growth of cytotoxic T cells against renal cell carcinoma, J IMMUNOTH, 23(1), 2000, pp. 83-93
Authors:
Belldegrun, A
Citation: A. Belldegrun, What's hot in the prostate?, PROSTATE C, 3(4), 2000, pp. 213-216
Authors:
Belldegrun, A
Shvarts, O
Figlin, RA
Citation: A. Belldegrun et al., Expanding the indications for surgery and adjuvant interleukin-2-based immunotherapy in patients with advanced renal cell carcinoma, CA J SCI AM, 6, 2000, pp. S88-S92
Authors:
Hoffman, DMJ
Gitlitz, BJ
Belldegrun, A
Figlin, RA
Citation: Dmj. Hoffman et al., Adoptive cellular therapy, SEMIN ONCOL, 27(2), 2000, pp. 221-233
Authors:
Pantuck, AJ
Zisman, A
Rauch, MK
Belldegrun, A
Citation: Aj. Pantuck et al., Incidental renal tumors, UROLOGY, 56(2), 2000, pp. 190-196
Authors:
Shvarts, O
Tsui, KH
Smith, RB
de Kernion, JB
Belldegrun, A
Citation: O. Shvarts et al., Blood loss and the need for transfusion in patients who undergo partial orradical nephrectomy for renal cell carcinoma, J UROL, 164(4), 2000, pp. 1160-1163
Authors:
Tsui, KH
Shvarts, O
Smith, RB
Figlin, RA
deKernion, JB
Belldegrun, A
Citation: Kh. Tsui et al., Prognostic indicators for renal cell carcinoma: A multivariate analysis of643 patients using the revised 1997 TNM staging criteria, J UROL, 163(4), 2000, pp. 1090-1095
Authors:
Tsui, KH
Shvarts, O
Smith, RB
Figlin, R
DeKernion, JB
Belldegrun, A
Citation: Kh. Tsui et al., Renal cell carcinoma: Prognostic significance of incidentally detected tumors, J UROL, 163(2), 2000, pp. 426-430
Authors:
Tsui, KH
Shvarts, O
Barbaric, Z
Figlin, R
DeKernion, JB
Belldegrun, A
Citation: Kh. Tsui et al., Is adrenalectomy a necessary component of radical nephrectomy? UCLA experience with 511 radical nephrectomies, J UROL, 163(2), 2000, pp. 437-441
Authors:
Pinthus, JH
Waks, T
Schindler, DG
Harmelin, A
Said, JW
Belldegrun, A
Ramon, J
Eshhar, Z
Citation: Jh. Pinthus et al., WISH-PC2: A unique xenograft model of human prostatic small cell carcinoma, CANCER RES, 60(23), 2000, pp. 6563-6567
Authors:
Belldegrun, A
Citation: A. Belldegrun, What's hot in the prostate?, PROSTATE C, 2(5-6), 1999, pp. 215-217
Authors:
van Ophoven, A
Ng, CP
Patel, B
Bonavida, B
Belldegrun, A
Citation: A. Van Ophoven et al., Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) for treatment of prostate cancer: first results and review of the literature, PROSTATE C, 2(5-6), 1999, pp. 227-233
Authors:
Belldegrun, A
Citation: A. Belldegrun, What's hot in the prostate?, PROSTATE C, 2(4), 1999, pp. 163-165
Authors:
Belldegrun, A
Citation: A. Belldegrun, What's hot in the prostate?, PROSTATE C, 2(2), 1999, pp. 55-57